Abstract: The present invention relates to the use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species.
Abstract: The present invention relates to the use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species.
Abstract: The invention relates to the expression of the cDNA clone for sub-units a1 (hsGCa1) and b1 (hsGCb1) of human soluble guanylylcyclase and the subsequent purification of the active enzyme and use thereof, the medical application of the expression of this clone by gene transfer, in addition to antibodies against peptides derived from said sequence and the use thereof.
Type:
Grant
Filed:
August 16, 1999
Date of Patent:
February 1, 2005
Assignee:
Vasopharm Biotech GmbH
Inventors:
Harald Schmidt, Ulrike Zabel, Wolfgang Poller
Abstract: Compounds of formula (I), where preferably: A=a bridge of partial formula (II) or (III), R1 and R2=independently (substituted) alkyl, aryl or aralkyl, or together form a heterocycle, R3=H, —CO-Alkyl, or —CO-Aryl, R4=Aryl, —CO—O-Aryl or —CO-Aryl and R5=H, are potent inhibitors of NO-synthase and are suitable as pharmaceutical agents of prophylaxis and treatment of disease states associates with a disturbed NO metabolism.
Type:
Grant
Filed:
September 11, 2000
Date of Patent:
January 18, 2005
Assignee:
Vasopharm Biotech GmbH
Inventors:
Wolfgang Pfleiderer, Harald Schmidt, Lothar Fröhlich, Peter Kotsonis, Shahriyar Taghavi-Moghadam
Abstract: The invention relates to antibodies against VASP (vasodilator-stimulated phosphoprotein) which only bind VASP as an antigen when VASP is present in phosphorylated form, to hybridoma cells for their preparation, and to the use of the antibodies or antibody fragments as diagnostic agents and/or therapeutic agents.
Type:
Application
Filed:
September 22, 2003
Publication date:
April 1, 2004
Applicant:
Vasopharm Biotech GmbH
Inventors:
Martin Eigenthaler, Heinz Hoschuetzky, Ulrich Walter
Abstract: The invention relates to antibodies against VASP (vasodilator-stimulated phosphoprotein) which only bind VASP as an antigen when VASP is present in phosphorylated form, to hybridoma cells for their preparation, and to the use of the antibodies or antibody fragments as diagnostic agents and/or therapeutic agents.
Type:
Grant
Filed:
June 21, 2000
Date of Patent:
November 18, 2003
Assignee:
Vasopharm Biotech GmbH
Inventors:
Martin Eigenthaler, Heinz Hoschuetzky, Ulrich Walter